NASDAQ:TTRX Turn Therapeutics (TTRX) Stock Price, News & Analysis $8.68 -0.67 (-7.11%) As of 03:42 PM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Turn Therapeutics Stock (NASDAQ:TTRX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Turn Therapeutics alerts:Sign Up Key Stats Today's Range$8.20▼$9.6450-Day Range$8.94▼$15.3452-Week Range$2.57▼$16.45Volume125,742 shsAverage Volume69,737 shsMarket Capitalization$265.53 millionP/E RatioN/ADividend YieldN/APrice Target$9.00Consensus RatingModerate Buy Company Overview Turn Therapeutics is a biotechnology company focused on developing topical products for skin health, wound care and infection management. Its work centers on formulations intended to deliver antimicrobial treatment directly to affected areas. The company has developed products for wound care and other topical applications, using its formulation technology to address needs in dermatology and related fields. Turn Therapeutics is based in the United States and has focused on developing and commercializing its products in the U.S. market.AI Generated. May Contain Errors. Read More Turn Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks27th Percentile Overall ScoreTTRX MarketRank™: 1.34217506631 of 5 starsTurn Therapeutics scored higher than 27% of companies evaluated by MarketBeat, and ranked 788th out of 877 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion2.3 / 5Analyst RatingModerate Buy Consensus RatingTurn Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 2 strong buy ratings, 1 buy rating, 2 hold ratings, and 1 sell rating.Upside/DownsideThe consensus price target for Turn Therapeutics is close to its current price, suggesting limited near-term upside or downside.Amount of Analyst CoverageTurn Therapeutics has only been the subject of 3 research reports in the past 90 days.Read more about Turn Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Turn Therapeutics are expected to grow in the coming year, from ($0.52) to ($0.37) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Turn Therapeutics is -19.91, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Turn Therapeutics is -19.91, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioTurn Therapeutics has a P/B Ratio of 53.62. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted3.94% of the float of Turn Therapeutics has been sold short.Short Interest Ratio / Days to CoverTurn Therapeutics has a short interest ratio ("days to cover") of 5.87.Change versus previous monthShort interest in Turn Therapeutics has recently increased by 23.03%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldTurn Therapeutics does not currently pay a dividend.Dividend GrowthTurn Therapeutics does not have a long track record of dividend growth. News and Social Media2.0 / 5News Sentiment0.22 News SentimentTurn Therapeutics has a news sentiment score of 0.22. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.59 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Turn Therapeutics this week, compared to 1 article on an average week.MarketBeat FollowsOnly 1 people have added Turn Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership0.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Turn Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders55.89% of the stock of Turn Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsTurn Therapeutics has minimal institutional ownership at this time.Read more about Turn Therapeutics' insider trading history. Receive TTRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Turn Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. TTRX Stock News HeadlinesTurn Therapeutics to Present at Jefferies Global Healthcare Conference in LondonNovember 16 at 7:42 AM | marketscreener.comMTurn Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2026November 9, 2026 | marketscreener.comMYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time through a temporary download link. He plans to charge for it soon. Download your copy now and lock it in at no cost, regardless of future pricing.November 16 at 1:00 AM | Profits Run (Ad)Turn Therapeutics Inc. GAAP EPS of -$0.21November 9, 2026 | seekingalpha.comTurn Therapeutics (NASDAQ:TTRX) Stock Rating Lowered by Wall Street ZenNovember 8, 2026 | americanbankingnews.comTurn Therapeutics’ GX-03 Earns "Developmental Immunology Solution of the Year" in 2026 BioTech Breakthrough Awards ProgramNovember 5, 2026 | finance.yahoo.comWBB Securities upgrades Turn Therapeutics to hold from sellOctober 23, 2026 | msn.comTurn Therapeutics Inc (TTRX)October 12, 2026 | investing.comSee More Headlines TTRX Stock Analysis - Frequently Asked Questions How have TTRX shares performed this year? Turn Therapeutics' stock was trading at $3.94 at the beginning of the year. Since then, TTRX shares have increased by 117.7% and is now trading at $8.5790. How were Turn Therapeutics' earnings last quarter? Turn Therapeutics Inc. (NASDAQ:TTRX) released its quarterly earnings data on Monday, November, 9th. The company reported ($0.21) earnings per share (EPS) for the quarter. When did Turn Therapeutics IPO? Turn Therapeutics (TTRX) raised $0 in an IPO on the week of October 13th 2025. The company issued 17,900,000 shares at a price of $0.00 per share. Clear Street served as the underwriter for the IPO. Who are Turn Therapeutics' major shareholders? Top institutional investors of Turn Therapeutics include SteelPeak Wealth LLC (0.84%), HighTower Advisors LLC (0.08%), Jump Financial LLC (0.05%) and Composition Wealth LLC (0.03%). Insiders that own company stock include Abraham Chesed, Arthur F Golden and Zuraiz Chaudhary. View institutional ownership trends. How do I buy shares of Turn Therapeutics? Shares of TTRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings11/09/2026Today11/16/2026Jefferies Global Healthcare Conference11/16/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (1m+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 TTRX's financial health is in the Green zone, according to TradeSmith. TTRX has been in this zone for over one month. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:TTRX CIK2023016 Webturntherapeutics.com Phone(818) 564-4011FaxN/AEmployees2Year FoundedN/APrice Target and Rating Average Price Target for Turn Therapeutics$9.00 High Price Target$10.00 Low Price Target$8.00 Potential Upside/Downside+3.6%Consensus RatingModerate Buy Rating Score (0-4)2.67 Research Coverage6 Analysts Profitability EPS (Trailing Twelve Months)($0.43) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$3.19 million Net MarginsN/A Pretax MarginN/A Return on Equity-261.87% Return on Assets-70.18% Debt Debt-to-Equity Ratio1.01 Current Ratio3.19 Quick Ratio3.19 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.16 per share Price / Book54.28Miscellaneous Outstanding Shares30,573,000Free Float13,486,000Market Cap$265.53 million OptionableOptionable BetaN/A 10 Best Stocks to Own in Fall 2026AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.Get This Free Report This page (NASDAQ:TTRX) was last updated on 11/16/2026 by MarketBeat.com Staff. From Our PartnersMy $247 scanner for $7Bill Poulos is cutting the price of his $247 Instant Scanner to $7 for Black Friday. It's a one-time payment t...Profits Run | SponsoredA Nasdaq drone company just landed a deal with a Philippine billionaire's groupA Nasdaq-listed drone company just signed an exclusive agreement with Prime Strategic Holdings, part of billio...The Tomorrow Investor | SponsoredWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...Base Camp Trading | SponsoredEvery Starlink dish pays this stockThere's a chip inside every Tesla and Starlink dish that Elon doesn't own. He pays royalties to use it. Now...Behind the Markets | SponsoredDrop these 5 stocks before the market opens tomorrow!The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratin...Weiss Ratings | SponsoredYour Social Security check is scheduled for a 22% cutThe U.S. now borrows money just to pay interest on money it already borrowed, a pattern economists call a debt...American Alternative | SponsoredPentagon magnet restrictions take effect January 1, 2027A NASDAQ-listed company has signed a term sheet outlining a potential 75-year agreement with the U.S. Army. It...OilPrice | SponsoredThe $40 trillion number nobody won on Tuesday will touchDemocrats took the House and Senate on election night, but the $40 trillion national debt and the $1 trillion ...Vault Metal | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Turn Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Turn Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.